文献速递神经眼科

非动脉炎性前部缺血性视神经病变的进展发生早且与可干预危险因素无关

Progression of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Occurs Early and Is Unassociated With Modifiable Risk Factors.
PubMed 文献 · Am J Ophthalmol · 2026-01-14

该研究基于QRK207多中心随机对照试验的二次病例对照分析,纳入599只急性NAION研究眼,评估视力和视野进展频率及危险因素。结果显示视力恶化在症状出现后22天内(至第8天)急性发生,糖尿病、高血压、高脂血症和心血管危险因素不增加进展风险,唯一与BCVA和视野进展均一致相关的因素是既往对侧眼NAION。

要点

  • NAION视力恶化主要发生在症状出现后22天内(至第8天),约91.6%的进展在此窗口内。
  • 糖尿病、高血压、高脂血症和心血管危险因素不增加NAION进展风险。
  • 既往对侧眼NAION是与BCVA和视野进展均一致相关的唯一因素。

核心结论

  • NAION视力恶化急性发生,心血管危险因素不是NAION进展的重要危险特征。
  • 既往对侧眼NAION是与BCVA和视野丢失进展均一致相关的唯一因素。

研究设计与样本

  • QRK207多中心、双盲、假手术对照随机临床试验的二次病例对照分析。
  • 分析599只急性NAION研究眼(来自729例前瞻性入组个体),均未接受治疗,有独立筛查和第1天(平均间隔2.5天)评估。
  • 第2个月分析仅纳入167只假注射研究眼。

主要发现

  • 筛查至第1天,7.3%(43/583)眼出现≥10 ETDRS字母丢失,4.1%眼出现≥15 ETDRS字母丢失。
  • 筛查至第2个月,167只假注射眼中21.6%(36/167)出现≥10 ETDRS字母丢失,14.4%(24/167)出现≥15 ETDRS字母丢失。
  • 36只进展眼中约91.6%(33/36)在症状出现后22天内(至第8天)进展。
  • 第1天至第2个月,139只假注射眼中18.7%出现≥10 ETDRS字母丢失,13.7%出现≥15 ETDRS字母丢失。
  • 筛查至第1天,32.1%(192/599)眼出现总偏差(TD)进展,66.1%保持稳定,1.8%改善。

关键数值与推荐

  • 进展定义为≥10 ETDRS字母丢失(也分析≥15 ETDRS字母丢失)或删失校正平均总偏差(avgTD)恶化,使用分位数回归定义进展和恢复阈值。
  • 既往对侧眼NAION和阻塞性睡眠呼吸暂停(OSA)与≥10 ETDRS字母丢失显著相关。
  • 仅既往对侧眼NAION仍是≥15 ETDRS字母丢失的危险因素。
  • 既往对侧眼NAION和高脂血症(HLD)与TD进展相关。

临床怎么用

  • 临床应认识到NAION视力恶化主要在发病早期(约22天内)发生,早期监测至关重要。
  • 心血管危险因素(糖尿病、高血压、高脂血症)不应作为NAION进展的可干预靶点来预测或预防视力恶化。
  • 既往对侧眼NAION病史提示进展风险较高,需加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the true frequency and risk factors for acute nonarteritic anterior ischemic optic neuropathy (NAION) progression and identify modifiable features to reduce vision worsening. DESIGN: Secondary case-control analysis of the QRK207 multicenter, double-masked, sham-controlled, randomized clinical trial. SUBJECTS: We analyzed 599 study eyes with acute NAION (of 729 individuals prospectively enrolled in the QRK207 trial) with separate screening and Day 1 (mean 2.5-day interval) evaluations for progression. No participants included in this analysis received treatment. The Month 2 analysis included only the 167 sham-injected study eyes. METHODS: Visual outcomes were assessed using best-corrected visual acuity (BCVA) using early treatment diabetic retinopathy study (ETDRS) charts and standardized automated perimetry. MAIN OUTCOME MEASURES: We defined progression as ≥10 ETDRS letter loss (also analyzed ≥15 ETDRS letter loss) or worsening of censored corrected average total deviation (avgTD) using quantile regression to define progression and recovery thresholds. We evaluated systemic and ophthalmic features associated with progression. RESULTS: From screening to Day 1, 7.3% (43/583) of eyes had ≥ 10 ETDRS letter loss, and 4.1% eyes had ≥ 15 ETDRS letter loss. Diabetes mellitus, hypertension, hyperlipidemia (HLD), and cardiovascular risk factors did not increase the risk of progression. Previous fellow-eye (FE) NAION and obstructive sleep apnea (OSA) were significantly associated with ≥10 ETDRS letter loss. Only FE NAION remained a risk factor ≥15 ETDRS letter loss. Of the 167 sham-injected eyes with screening to Month 2 evaluation, 21.6% (36/167) had ≥10 ETDRS letter loss, and 14.4% (24/167) had ≥15 ETDRS letter loss. About 91.6% of eyes (33/36) progressed within 22 days of symptom onset (by Day 8). Of the 139 sham-injected eyes with Day 1 to Month 2 evaluation, 18.7% had ≥10 ETDRS letter loss, and 13.7% had ≥15 ETDRS letter loss. TD progression from screening to Day 1 occurred in 32.1% (192/599) eyes, 66.1% remained stable, and 1.8% improved. FE NAION and HLD were associated with TD progression. CONCLUSIONS: Worsening of vision in NAION occurs acutely. The results do not support cardiovascular risk factors as important hazard features for NAION progression. The only consistent factor associated with progression for both BCVA and VF loss was previous FE NAION.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Williams ZR, Morgenstern R, Erekat AN, et al. Progression of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Occurs Early and Is Unassociated With Modifiable Risk Factors. Am J Ophthalmol. 2026. PMID: 41544737. doi:10.1016/j.ajo.2026.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。